found that PD-1/PD-L1 inhibitors in combination with radiotherapy and antiangiogenic therapy could improve the mOS to 22.4 months and the objective response rate (ORR) to 40% with low toxicity in advanced HCC patients (9). This evidence concerns the gene CD274 and hepatocellular carcinoma.